{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T21:50:55Z","timestamp":1762033855640},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T00:00:00Z","timestamp":1621209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T00:00:00Z","timestamp":1621209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The present study aimed to investigate whether the serum biomarkers of immune response orchestrate the seroconversion status in patients with autoimmune diseases (AID) upon planned primary 17DD-YF vaccination. For this purpose a total of 161 individuals were enrolled in a prospective study, including patients with Rheumatoid Arthritis (RA\u2009=\u200938), Spondyloarthritis (SpA\u2009=\u200951), Systemic Lupus Erythematosus (SLE\u2009=\u200921) and Sj\u00f6gren\u2019s Syndrome (SS\u2009=\u200930) along with a group of healthy controls (HC\u2009=\u200921). Analysis of plaque reduction neutralization test (PRNT) titers and seropositivity rates along with the 17DD-YF viremia and serum biomarkers were carried out at distinct time points (D0\/D3\u20134\/D5\u20136\/D7\/D14\u201328). The results demonstrated an overall lower PRNT titer and seropositivity rate (170 vs. 448; 77 vs. 95%) in AID as compared to HC, especially in SpA and SLE subgroups. No significant differences were observed in the viremia levels amongst groups. In general, a more prominent serum biomarker response was observed in AID as compared to HC, throughout the timeline kinetics. Remarkably, AID\/PRNT(\u2212) exhibited higher levels of several biomarkers at baseline as compared to AID\/PRNT+. Moreover, while AID\/PRNT(+) exhibited earlier increase in serum biomarkers at D3\u20134\/D5\u20136, the AID\/PRNT(\u2212) displayed higher response at later time points (D7\/D14\u2013D28). Of note, a synchronic increase of IFN-\u03b3 at the peak of viremia (D5\u20136) was observed in HC and AID\/PRNT(+) groups, whereas a later asynchronous IFN-\u03b3 response was reported for AID\/PRNT(\u2212) at D7. The biomarker profile tends to deflate at post-vaccination timeline, highlighting a putative immunomodulatory effect of live attenuated 17DD-YF vaccine in AID\/PRNT(+), but not in AID\/PRNT(\u2212). Altogether these data suggested that inflammatory status prior vaccination, low IFN-\u03b3 at viremia peak and the occurrence of asynchronous biomarker storm after 17DD-YF vaccination may orchestrate the lack of neutralizing antibody response \u03b3.<\/jats:p>","DOI":"10.1038\/s41598-021-89770-8","type":"journal-article","created":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T10:04:53Z","timestamp":1621245893000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Serum biomarker profile orchestrating the seroconversion status of patients with autoimmune diseases upon planned primary 17DD Yellow fever vaccination"],"prefix":"10.1038","volume":"11","author":[{"given":"Ismael Artur","family":"da Costa-Rocha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ketty Lysie Libardi Lira","family":"Machado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Carolina","family":"Campi-Azevedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9a","family":"Teixeira-Carvalho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Peruhype-Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheila Maria Barbosa","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily Hime","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gisela Freitas","family":"Trindade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thays Zanon","family":"Casagrande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samira Tatiyama","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e1vio Carvalho","family":"Deotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafaela Villa Real","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priscila Costa Martins","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica Vieira","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valquiria Garcia","family":"Dinis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00f4nia Alves","family":"Gouv\u00eaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Bernadete Renoldi de Oliveira","family":"Gavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidia Balarini","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben Horst","family":"Duque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Paula Esp\u00edndula","family":"Gianordoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria de Fatima","family":"Bissoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria da Penha Gomes","family":"Gouvea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauro Ferreira da Silva","family":"Pinto-Neto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Paula Neves","family":"Burian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francieli Fontana Sutile Tardetti","family":"Fantinato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gecilmara Salviato","family":"Pileggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Licia Maria Henrique","family":"da Mota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9ria","family":"Valim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olindo Assis","family":"Martins-Filho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,17]]},"reference":[{"key":"89770_CR1","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jcv.2014.08.030","volume":"64","author":"TP Monath","year":"2015","unstructured":"Monath, T. P. & Vasconcelos, P. F. Yellow fever. J. Clin. Virol. 64, 160\u2013173. https:\/\/doi.org\/10.1016\/j.jcv.2014.08.030 (2015).","journal-title":"J. Clin. Virol."},{"issue":"11","key":"89770_CR2","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.tim.2018.05.012","volume":"26","author":"F Douam","year":"2018","unstructured":"Douam, F. & Ploss, A. Yellow fever virus: knowledge gaps impeding the fight against an old foe. Trends Microbiol. 26(11), 913\u2013928. https:\/\/doi.org\/10.1016\/j.tim.2018.05.012 (2018).","journal-title":"Trends Microbiol."},{"issue":"1","key":"89770_CR3","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.antiviral.2007.10.009","volume":"78","author":"TP Monath","year":"2008","unstructured":"Monath, T. P. Treatment of yellow fever. Antiviral Res. 78(1), 116\u2013124. https:\/\/doi.org\/10.1016\/j.antiviral.2007.10.009 (2008).","journal-title":"Antiviral Res."},{"issue":"3","key":"89770_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s11908-017-0566-9","volume":"19","author":"ND Collins","year":"2017","unstructured":"Collins, N. D. & Barrett, A. D. Live attenuated yellow fever 17D vaccine: a legacy vaccine still controlling outbreaks in modern day. Curr. Infect. Dis. Rep. 19(3), 14. https:\/\/doi.org\/10.1007\/s11908-017-0566-9 (2017).","journal-title":"Curr. Infect. Dis. Rep."},{"key":"89770_CR5","volume-title":"A Global Strategy to Eliminate Yellow Fever Epidemics (EYE) 2017\u20132026","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. A Global Strategy to Eliminate Yellow Fever Epidemics (EYE) 2017\u20132026 (World Health Organization, Geneva, 2018)."},{"issue":"4","key":"89770_CR6","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1586\/erv.12.6","volume":"11","author":"TP Monath","year":"2012","unstructured":"Monath, T. P. Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Rev. Vaccines. 11(4), 427\u2013448. https:\/\/doi.org\/10.1586\/erv.12.6 (2012).","journal-title":"Expert Rev. Vaccines."},{"issue":"5","key":"89770_CR7","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1590\/s0034-89102004000500009","volume":"38","author":"LAB Camacho","year":"2004","unstructured":"Camacho, L. A. B. et al. Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial. Rev. Sa\u00fade P\u00fabl. 38(5), 671\u2013678. https:\/\/doi.org\/10.1590\/s0034-89102004000500009 (2004).","journal-title":"Rev. Sa\u00fade P\u00fabl."},{"issue":"2","key":"89770_CR8","doi-asserted-by":"publisher","first-page":"e001035","DOI":"10.1136\/rmdopen-2019-001035","volume":"5","author":"C Rondaan","year":"2019","unstructured":"Rondaan, C. et al. Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations. RMD Open 5(2), e001035. https:\/\/doi.org\/10.1136\/rmdopen-2019-001035 (2019).","journal-title":"RMD Open"},{"issue":"6","key":"89770_CR9","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.jinf.2016.02.017","volume":"72","author":"RW Wieten","year":"2016","unstructured":"Wieten, R. W. et al. 17D yellow fever vaccine elicits comparable long-term immune responses in healthy individuals and immune-compromised patients. J. Infect. 72(6), 713\u2013722. https:\/\/doi.org\/10.1016\/j.jinf.2016.02.017 (2016).","journal-title":"J. Infect."},{"issue":"10","key":"89770_CR10","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.vaccine.2016.01.037","volume":"34","author":"RW Wieten","year":"2016","unstructured":"Wieten, R. W. et al. Comparison of the PRNT and an immune fluorescence assay in yellow fever vaccinees receiving immunosuppressive medication. Vaccine. 34(10), 1247\u20131251. https:\/\/doi.org\/10.1016\/j.vaccine.2016.01.037 (2016).","journal-title":"Vaccine."},{"issue":"3","key":"89770_CR11","doi-asserted-by":"publisher","first-page":"e0149871","DOI":"10.1371\/journal.pone.0149871","volume":"11","author":"RW Wieten","year":"2016","unstructured":"Wieten, R. W. et al. A single 17D yellow fever vaccination provides lifelong immunity) characterization of yellow-fever-specific neutralizing antibody and T-cell responses after vaccination. PLoS ONE 11(3), e0149871. https:\/\/doi.org\/10.1371\/journal.pone.0149871 (2016).","journal-title":"PLoS ONE"},{"issue":"2","key":"89770_CR12","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/art.38960","volume":"67","author":"AC Oliveira","year":"2015","unstructured":"Oliveira, A. C. et al. Seroconversion in patients with rheumatic diseases treated with immunomodulators or immunosuppressants, who were inadvertently revaccinated against yellow fever. Arthritis Rheumatol. 67(2), 582\u2013583. https:\/\/doi.org\/10.1002\/art.38960 (2015).","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"89770_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s42358-019-0056-x","volume":"59","author":"GS Pileggi","year":"2019","unstructured":"Pileggi, G. S. et al. Brazilian recommendations on the safety and effectiveness of the yellow fever vaccination in patients with chronic immune-mediated inflammatory diseases. Adv. Rheumatol. 59(1), 17. https:\/\/doi.org\/10.1186\/s42358-019-0056-x (2019).","journal-title":"Adv. Rheumatol."},{"key":"89770_CR14","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.3389\/fimmu.2020.01382","volume":"11","author":"V Valim","year":"2020","unstructured":"Valim, V. et al. Planned yellow fever primary vaccination is safe and immunogenic in patients with autoimmune diseases: a prospective non-interventional study. Front. Immunol. 11, 1382. https:\/\/doi.org\/10.3389\/fimmu.2020.01382 (2020).","journal-title":"Front. Immunol."},{"key":"89770_CR15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/j.1365-2249.2006.03317.x","volume":"148","author":"MA Martins","year":"2007","unstructured":"Martins, M. A. et al. Activation\/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: is this the key to prevent severe adverse reactions following immunization?. Clin. Exp. Immunol. 148, 90\u2013100. https:\/\/doi.org\/10.1111\/j.1365-2249.2006.03317.x (2007).","journal-title":"Clin. Exp. Immunol."},{"key":"89770_CR16","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.vaccine.2007.12.035","volume":"26","author":"MA Martins","year":"2008","unstructured":"Martins, M. A. et al. Innate immunity phenotypic features point toward simultaneous raise of activation and modulation events following 17DD live attenuated yellow fever first-time vaccination. Vaccine. 26, 1173\u20131184. https:\/\/doi.org\/10.1016\/j.vaccine.2007.12.035 (2008).","journal-title":"Vaccine."},{"key":"89770_CR17","doi-asserted-by":"publisher","first-page":"7919","DOI":"10.4049\/jimmunol.0803903","volume":"183","author":"RS Akondy","year":"2009","unstructured":"Akondy, R. S. et al. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J. Immunol. 183, 7919\u20137930. https:\/\/doi.org\/10.4049\/jimmunol.0803903 (2009).","journal-title":"J. Immunol."},{"issue":"2","key":"89770_CR18","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1080\/21645515.2015.1082693","volume":"12","author":"AC Campi-Azevedo","year":"2016","unstructured":"Campi-Azevedo, A. C. et al. Booster dose after 10 years is recommended following 17DD-YF primary vaccination. Hum. Vaccines Immunother. 12(2), 491\u2013502. https:\/\/doi.org\/10.1080\/21645515.2015.1082693 (2016).","journal-title":"Hum. Vaccines Immunother."},{"issue":"6","key":"89770_CR19","doi-asserted-by":"publisher","first-page":"e0006462","DOI":"10.1371\/journal.pntd.0006462","volume":"12","author":"C Costa-Pereira","year":"2018","unstructured":"Costa-Pereira, C. et al. Multi-parameter approach to evaluate the timing of memory status after 17DD-YF primary vaccination. PLoS Negl. Trop. Dis. 12(6), e0006462. https:\/\/doi.org\/10.1371\/journal.pntd.0006462 (2018).","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"14","key":"89770_CR20","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1186\/1471-2334-14-391","volume":"15","author":"AC Campi-Azevedo","year":"2014","unstructured":"Campi-Azevedo, A. C. et al. Subdoses of 17DD yellow fever vaccine elicit equivalent virological\/immunological kinetics timeline. BMC Infect. Dis. 15(14), 391. https:\/\/doi.org\/10.1186\/1471-2334-14-391 (2014).","journal-title":"BMC Infect. Dis."},{"issue":"6","key":"89770_CR21","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/infdis\/jir439","volume":"204","author":"M Luiza-Silva","year":"2011","unstructured":"Luiza-Silva, M. et al. Cytokine signatures of innate and adaptive immunity in 17DD yellow fever vaccinated children and its association with the level of neutralizing antibody. J. Infect. Dis. 204(6), 873\u2013883. https:\/\/doi.org\/10.1093\/infdis\/jir439 (2011).","journal-title":"J. Infect. Dis."},{"issue":"12","key":"89770_CR22","doi-asserted-by":"publisher","first-page":"e83776","DOI":"10.1371\/journal.pone.0083776","volume":"8","author":"C Kyogoku","year":"2013","unstructured":"Kyogoku, C. et al. Cell-specific type I IFN signatures in autoimmunity and viral infection: what makes the difference?. PLoS ONE 8(12), e83776. https:\/\/doi.org\/10.1371\/journal.pone.0083776 (2013).","journal-title":"PLoS ONE"},{"key":"89770_CR23","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11882-014-0489-6","volume":"15","author":"JA Smith","year":"2015","unstructured":"Smith, J. A. Update on ankylosing spondylitis: current concepts in pathogenesis. Curr. Allergy Asthma Rep. 15, 489. https:\/\/doi.org\/10.1007\/s11882-014-0489-6 (2015).","journal-title":"Curr. Allergy Asthma Rep."},{"issue":"9","key":"89770_CR24","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1136\/annrheumdis-2019-215356","volume":"78","author":"DG McGonagle","year":"2019","unstructured":"McGonagle, D. G., McInnes, I. B., Kirkham, B. W., Sherlock, J. & Moots, R. The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. Ann. Rheum. Dis. 78(9), 1167\u20131178. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215356 (2019).","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"89770_CR25","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha, D. et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 62(9), 2569\u20132581. https:\/\/doi.org\/10.1002\/art.27584 (2010).","journal-title":"Arthritis Rheum."},{"issue":"7","key":"89770_CR26","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s00393-009-0510-y","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit, M., Braun, J. & Sieper, J. Assessment of SpondyloArthritis international Society. ASAS classification criteria for axial spondyloarthritis. Z Rheumatol. 68(7), 591\u2013593. https:\/\/doi.org\/10.1007\/s00393-009-0510-y (2009).","journal-title":"Z Rheumatol."},{"issue":"1","key":"89770_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.2010.133645","volume":"70","author":"M Rudwaleit","year":"2011","unstructured":"Rudwaleit, M. et al. The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann. Rheum. Dis. 70(1), 25\u201331. https:\/\/doi.org\/10.1136\/ard.2010.133645 (2011).","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"89770_CR28","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/art.34473","volume":"64","author":"M Petri","year":"2012","unstructured":"Petri, M. et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 64(8), 2677\u20132686. https:\/\/doi.org\/10.1002\/art.34473 (2012).","journal-title":"Arthritis Rheum."},{"issue":"11","key":"89770_CR29","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen, F. et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative. Arthritis Rheum. 65(11), 2737\u20132747. https:\/\/doi.org\/10.1002\/art.38098 (2013).","journal-title":"Arthritis Rheum."},{"issue":"1","key":"89770_CR30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.39859","volume":"69","author":"CH Shiboski","year":"2017","unstructured":"Shiboski, C. H. et al. 2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary sjogren\u2019s syndrome. a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheum. 69(1), 35\u201345. https:\/\/doi.org\/10.1002\/art.39859 (2017).","journal-title":"Arthritis Rheum."},{"issue":"6","key":"89770_CR31","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.biologicals.2012.09.005","volume":"40","author":"M Sim\u00f5es","year":"2012","unstructured":"Sim\u00f5es, M. et al. Evaluation of accuracy and reliability of the plaque reduction neutralization test (micro-PRNT) in detection of yellow fever virus antibodies. Biologicals 40(6), 399\u2013404. https:\/\/doi.org\/10.1016\/j.biologicals.2012.09.005 (2012).","journal-title":"Biologicals"},{"issue":"4","key":"89770_CR32","doi-asserted-by":"publisher","first-page":"879","DOI":"10.4161\/hv.22982","volume":"9","author":"RM Martins","year":"2013","unstructured":"Martins, R. M. et al. 17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study. Hum. Vaccines Immunother. 9(4), 879\u2013888. https:\/\/doi.org\/10.4161\/hv.22982 (2013).","journal-title":"Hum. Vaccines Immunother."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89770-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89770-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89770-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T08:27:16Z","timestamp":1670056036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89770-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,17]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["89770"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-89770-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,17]]},"assertion":[{"value":"14 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10431"}}